JP2008545715A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545715A5
JP2008545715A5 JP2008513812A JP2008513812A JP2008545715A5 JP 2008545715 A5 JP2008545715 A5 JP 2008545715A5 JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008545715 A5 JP2008545715 A5 JP 2008545715A5
Authority
JP
Japan
Prior art keywords
composition
betacellulin
effective amount
therapeutically effective
situation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/020797 external-priority patent/WO2006128125A2/en
Publication of JP2008545715A publication Critical patent/JP2008545715A/ja
Publication of JP2008545715A5 publication Critical patent/JP2008545715A5/ja
Pending legal-status Critical Current

Links

JP2008513812A 2005-05-27 2006-05-30 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物 Pending JP2008545715A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US68570205P 2005-05-27 2005-05-27
US70206505P 2005-07-22 2005-07-22
US70196405P 2005-07-22 2005-07-22
US70149005P 2005-07-22 2005-07-22
US73379105P 2005-11-07 2005-11-07
US73686605P 2005-11-16 2005-11-16
US77816906P 2006-02-27 2006-02-27
US80044306P 2006-05-16 2006-05-16
PCT/US2006/020797 WO2006128125A2 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US11/442,244 US20070054851A1 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases

Publications (2)

Publication Number Publication Date
JP2008545715A JP2008545715A (ja) 2008-12-18
JP2008545715A5 true JP2008545715A5 (https=) 2009-09-10

Family

ID=37452973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513812A Pending JP2008545715A (ja) 2005-05-27 2006-05-30 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物

Country Status (6)

Country Link
US (1) US20070054851A1 (https=)
EP (1) EP1890722A2 (https=)
JP (1) JP2008545715A (https=)
AU (1) AU2006249327A1 (https=)
CA (1) CA2609728A1 (https=)
WO (1) WO2006128125A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605561A (zh) * 2006-12-22 2009-12-16 诺韦利克斯治疗有限公司 通过至少一种表皮生长因子受体特异性抗体或其衍生物的糖尿病治疗
EP2173407B1 (en) * 2007-07-02 2020-02-19 Roche Diabetes Care GmbH A device for drug delivery
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
US20130072437A1 (en) * 2010-05-28 2013-03-21 Mind-Nrg Sa Neuregulin isoforms,neuregulin polypeptides and uses thereof
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
EP3190418B1 (en) 2011-07-28 2019-05-01 metanomics GmbH Use of sm_sphingomyelin (d18:1, c16:0) as a marker for heart failure
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
JP6935403B2 (ja) * 2015-12-22 2021-09-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー サルコペニア及びフレイルの処置方法
KR101908056B1 (ko) 2017-05-25 2018-12-18 가천대학교 산학협력단 근아세포의 전기적 임피던스 모니터링 시스템 및 방법
WO2021198369A1 (en) * 2020-03-31 2021-10-07 Panda Jonas Songhomitra Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof
WO2025170936A1 (en) * 2024-02-05 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and methods for treating cardiac dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099304T3 (es) * 1992-02-10 1997-05-16 Takeda Chemical Industries Ltd Mitogeno de la musculatura lisa y adn que lo codifica.
US6232288B1 (en) * 1995-11-09 2001-05-15 Takeda Chemical Industries, Ltd. Composition for improving pancreatic function
JP3945846B2 (ja) * 1995-11-09 2007-07-18 武田薬品工業株式会社 膵臓機能改善剤
PT1148129E (pt) * 1998-12-09 2007-09-05 Takeda Pharmaceutical Modificação de betacelulina
AU4209300A (en) * 1999-04-06 2000-10-23 Genentech Inc. Use of erbb receptor ligands in treating diabetes
ATE364315T1 (de) * 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US6815418B2 (en) * 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
AUPQ496900A0 (en) * 2000-01-06 2000-02-03 Gropep Pty Ltd Growth factor splice variant
AU2001274947B2 (en) * 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040132679A1 (en) * 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation
US20060035844A1 (en) * 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia

Similar Documents

Publication Publication Date Title
JP2008545715A5 (https=)
JP2020033360A5 (https=)
HRP20131120T1 (hr) Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa
JP2011500850A5 (https=)
JP2013541576A5 (https=)
BRPI0818687A2 (pt) composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
NO20084919L (no) Oksadiazolidindionforbindelse
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
JP2011241213A5 (https=)
NZ594044A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
MX2011007371A (es) Metodo para tratar la hiperglucemia con la molecula.
WO2007139941A3 (en) Composition and methods for treatment of congestive heart failure
JP2019517542A5 (https=)
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
ME01546B (me) Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2018509419A5 (https=)
JP2013541583A5 (https=)
JP2021529829A5 (https=)
NZ591408A (en) Paracetamol and Calcium carbonate composition
JP2008545703A5 (https=)
JP2020536121A5 (https=)
JP2007119497A5 (https=)
JP2011500589A5 (https=)